Jefferies maintained Bristol-Myers Squibb (NYSE: BMY ) with a Buy rating and raisd the price target from $39.00 to $41.00. Jefferies said, "2013 will likely deliver several major catalysts that will shape the direction of Bristol-Myers' mid to long term growth. We believe that Eliquis will beat launch expectations providing